Francis Sarena
Chief Operating Officer at Apexigen America, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Xiao Dong Yang | M | 64 |
Apexigen America, Inc.
 Apexigen America, Inc. Pharmaceuticals: MajorHealth Technology Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA. | 14 years |
| Herbert Cross | M | 52 |
Abbott Biotherapeutics Corp.
 Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA.
Apexigen America, Inc.
Apexigen America, Inc. Pharmaceuticals: MajorHealth Technology Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA. | 5 years |
| Daniel Zabrowski | M | 64 |
Apexigen America, Inc.
Apexigen America, Inc. Pharmaceuticals: MajorHealth Technology Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA. | 10 years |
| Gordon Ringold | M | 73 |
Apexigen America, Inc.
Apexigen America, Inc. Pharmaceuticals: MajorHealth Technology Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA. | 4 years |
| John McLaughlin | M | 72 | 16 years | |
| Scott Smith | M | 61 |
Apexigen America, Inc.
Apexigen America, Inc. Pharmaceuticals: MajorHealth Technology Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA. | 5 years |
| Jakob Dupont | M | 58 |
Apexigen America, Inc.
Apexigen America, Inc. Pharmaceuticals: MajorHealth Technology Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA. | 4 years |
| Amy Wong | F | 58 |
Apexigen America, Inc.
Apexigen America, Inc. Pharmaceuticals: MajorHealth Technology Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA. | 10 years |
| Mark Nevins | M | - |
Apexigen America, Inc.
Apexigen America, Inc. Pharmaceuticals: MajorHealth Technology Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA. | - |
| Ovid C. Trifan | M | - |
Apexigen America, Inc.
Apexigen America, Inc. Pharmaceuticals: MajorHealth Technology Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA. | 10 years |
| Warren E. Pickett | M | 75 |
University of California, Berkeley
| 27 years |
| Daniel M. Kammen | M | 62 |
University of California, Berkeley
| 25 years |
| Meenu Chhabra Karson | F | 51 |
Apexigen America, Inc.
Apexigen America, Inc. Pharmaceuticals: MajorHealth Technology Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA. | 2 years |
| Michael Franklin | M | - |
University of California, Berkeley
| 25 years |
| Ronald Kurtz | M | 61 |
University of California, Berkeley
| 24 years |
| William J. Rutter | M | - |
Apexigen America, Inc.
Apexigen America, Inc. Pharmaceuticals: MajorHealth Technology Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA. | - |
| Timothy Duane | M | - |
University of California, Berkeley
| 25 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Aron M. Knickerbocker | M | 54 | 10 years | |
| Faheem Hasnain | M | 65 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 years |
| L. Tracee Whitley | F | - |
BMC Partners LLP
 BMC Partners LLP Miscellaneous Commercial ServicesCommercial Services BMC Partners LLP provides litigation, corporate, finance, restructuring, employment and benefits, and intellectual property services in all industries. It also offers consulting and advisory services in government, investment management, and mergers and acquisitions. The company was founded on July 1, 2002 and is headquartered in Boston, MA. | - |
| Lewis Williams | M | 74 | 18 years | |
| William Ringo | M | 78 | 7 years | |
| Mark McDade | M | 69 | 16 years | |
| Luis Borges | M | 62 | 5 years | |
| R. Lee Douglas | M | 72 | 15 years | |
| Bradford Goodwin | M | 69 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 4 years |
| Thomas Civik | M | 55 | 1 years | |
| Julia Gregory | F | 71 | 3 years | |
| Andrew Lipman | M | 72 |
BMC Partners LLP
BMC Partners LLP Miscellaneous Commercial ServicesCommercial Services BMC Partners LLP provides litigation, corporate, finance, restructuring, employment and benefits, and intellectual property services in all industries. It also offers consulting and advisory services in government, investment management, and mergers and acquisitions. The company was founded on July 1, 2002 and is headquartered in Boston, MA. | 8 years |
| Leonard Patrick Gage | M | 81 | 5 years | |
| Brian Atwood | M | 71 | 14 years | |
| S Chu Schubert | M | 51 |
University of California, Berkeley
| 8 years |
| Ilan Gur | M | - |
University of California, Berkeley
| 8 years |
| Linda Rubinstein | F | 58 | 4 years | |
| Sheila Gujrathi | M | 53 | 4 years | |
| Cho Yee Wan | M | 55 |
San Francisco State University
| 6 years |
| Bambang Susantono | M | 60 |
University of California, Berkeley
| 3 years |
| Frank Hsu | M | 63 | - | |
| Todd Hodes | M | - |
University of California, Berkeley
| 5 years |
| Garry Nicholson | M | 69 | 4 years | |
| Robert Steven Sikorski | M | - | 3 years | |
| Jen L. Neumann | F | - |
University of California, Berkeley
| 4 years |
| Arvin Fibrianto Iskandar | M | 55 |
San Francisco State University
| 6 years |
| Carol Schafer | F | 60 | 2 years | |
| Matthew A. O'Hara | M | - |
University of California, Berkeley
| 3 years |
| Michael Gibbs | M | 53 |
BMC Partners LLP
BMC Partners LLP Miscellaneous Commercial ServicesCommercial Services BMC Partners LLP provides litigation, corporate, finance, restructuring, employment and benefits, and intellectual property services in all industries. It also offers consulting and advisory services in government, investment management, and mergers and acquisitions. The company was founded on July 1, 2002 and is headquartered in Boston, MA. | 7 years |
| Lori Lyons-Williams | F | 46 | 2 years | |
| Laura Parada | M | - |
University of California, Berkeley
| 5 years |
| Martin Forrest | M | - | 2 years | |
| Kevin P. Baker | M | 63 | 12 years | |
| Ki-Ha Lee | M | - |
University of California, Berkeley
| 5 years |
| Liran Amrany | M | - |
University of California, Berkeley
| 6 years |
| Yi Ma | M | 51 |
University of California, Berkeley
| 4 years |
| Daniel K. Nomura | M | - |
University of California, Berkeley
| 9 years |
| Kimberly Kurtis | M | 51 |
University of California, Berkeley
| 4 years |
| Claire Chang | F | - |
San Francisco State University
| 4 years |
| Meenu Karson | F | 52 | 1 years | |
| John Windover | M | - |
University of California, Berkeley
| 5 years |
| Jillian Misrack | F | - |
San Francisco State University
| 4 years |
| Cecilia Kwan | F | - |
San Francisco State University
| 8 years |
| Nickhil Jakatdar | M | - |
University of California, Berkeley
| 4 years |
| Cynthia Shumate | F | 62 | 4 years | |
| Jaisim Shah | M | 63 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 9 years |
| Fred Cohen | M | 67 | 16 years | |
| Peder Jensen | M | 69 | 10 years | |
| William Duke | M | 51 | 1 years | |
| Mark McCamish | M | 72 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 years |
| Ami Knoefler | F | - |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 4 years |
| David White | M | 59 | 2 years | |
| Andrew Guggenhime | M | 55 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 4 years |
| Mohanbir Singh Gyani | M | 72 |
San Francisco State University
| 4 years |
| Maninder Hora | M | 70 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 4 years |
| Jeff P. Coon | M | 61 | 5 years | |
| Joel Drescher | M | - |
University of California, Berkeley
| 5 years |
| Kapil Dhingra | M | 64 | 6 years | |
| Paul W. Sandman | M | 76 | 12 years | |
| Franklin Berger | M | 74 | 11 years | |
| Gary Lyons | M | 73 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 years |
| Jon Saxe | M | 88 | 19 years | |
| Jonathan Graham | M | 63 | - | |
| Richard Murray | M | 65 | 5 years | |
| Kenneth Fong | M | - |
Apexigen America, Inc.
Apexigen America, Inc. Pharmaceuticals: MajorHealth Technology Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA. | - |
| Erik Dmytruk | M | - |
University of California, Berkeley
| 4 years |
| Christopher Thomas Downing | M | - |
University of California, Berkeley
| 3 years |
| Abu Ramin | M | - |
University of California, Berkeley
| 4 years |
| Mitzi Chang | F | - |
University of California, Berkeley
| 4 years |
| Thomas Barber | M | 50 |
University of California, Berkeley
| 2 years |
| Iman Movahed | M | - |
University of California, Berkeley
| 4 years |
| Richard Abramson | M | - |
University of California, Berkeley
| 3 years |
| Seth D. Greenstein | M | - |
University of California, Berkeley
| 5 years |
| Jay Traeger | M | - |
University of California, Berkeley
| 4 years |
| I Yin Hsu | F | 50 |
University of California, Berkeley
| 4 years |
| Ryan Goodman | M | - |
University of California, Berkeley
| 4 years |
| Alan Williams | M | - |
University of California, Berkeley
| 3 years |
| Hong Bin Cai | M | 56 |
University of California, Berkeley
| 8 years |
| Leon E. Chen | M | 49 |
University of California, Berkeley
| 4 years |
| Satoshi Akutsu | M | 57 |
University of California, Berkeley
| 3 years |
| Tom Beerle | M | - |
University of California, Berkeley
| 4 years |
| David Cheung | M | - |
University of California, Berkeley
| 4 years |
| Margo Diamond | M | - |
University of California, Berkeley
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 97 | 97.00% |
| Japan | 3 | 3.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Francis Sarena
- Personal Network
